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Abstract
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The Caenorhabditis elegans model is a rapid and inexpensive method to address pharmacologic
questions. We describe the use of C. elegans to explore 2 pharmacologic questions concerning
candidate antiobesity drugs and illustrate its potential usefulness in pharmacologic research: (1) to
determine a ratio of betahistine–olanzapine that blocks the olanzapine-induced intestinal fat
deposition (IFD) as detected by Nile red staining and (2) to identify the mechanism of action of a
pharmaceutical candidate AB-101 that reduces IFD. Olanzapine (53 μg/mL) increased the IFD
(12.1 ± 0.1%, P < 0.02), which was blocked by betahistine (763 μg/mL, 39.3 ± 0.01%, P < 0.05) in
wild-type C. elegans (N2). AB-101 (1.0%) reduced the IFD in N2 (P < 0.05), increased the
pharyngeal pumping rate (P < 0.05), and reversed the elevated IFD induced by protease inhibitors
atazanavir and ritonavir (P < 0.05). AB-101 did not affect IFD in a ACS null mutant strain
acs-4(ok2872) III/hT2[bli-4(e937) let-?(q782) qIs48](I;III) suggesting an involvement of the lipid
oxidation pathway and an upregulation of CPT-1. Our studies suggest that C. elegans may be used
as a resource in pharmacologic research. This article is intended to stimulate a greater appreciation
of its value in the development of new pharmaceutical interventions.
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Obesity pharmaceutical research to define drug mechanisms of action and develop drug
dosing information has been typically performed in rodent animal models. Caenorhabditis
elegans is a model organism that provides advantages by giving quicker answers at a
reduced cost, even if results require confirmation in rodents or other animal species later. We
used C. elegans to determine the approximate dosing ratio for an antiobesity drug being
developed to combat olanzapine-induced weight gain. Rapid metabolism of the candidate
antiobesity drug made pharmacokinetic studies impractical, but the constant presence of the
drugs in the media with C. elegans obviates this problem, which would have been a problem
in rodents. We also demonstrated that C. elegans can be used to determine the mechanism by
which a candidate antiobesity drug might cause weight loss. We describe these studies in the
hope that broader use of the C. elegans model organism will help to speed the pace and
reduce the cost of developing pharmaceuticals for the treatment of obesity and other
diseases.

Author Manuscript

The nematode animal model, C. elegans, is easy to genetically modify, and many mutations
of specific genes are inexpensively available.1 The C. elegans Genetics Center (CGC, UMN)
is funded by National Institutes of Health, which maintains and provides a variety of strains.
C. elegans is easy to maintain with a short lifespan in the laboratory, grows on agar in petri
dishes with the standard laboratory food being nontoxogenic Escherichia coli (OP50), and
favors rapid research results. Approximately, 300 gene inactivations in C. elegans have been
shown to cause fat reduction, and approximately, 100 gene inactivations cause fat
accumulation.2 Although C. elegans has been used for large-scale, high-throughput
screenings to discover drugs and bioactive materials, it has been less commonly used in dose
selection or for defining mechanisms of drug action.3

Author Manuscript

C. elegans deposits fat for energy storage along its intestinal tract. The translucent bodies of
the nematodes are convenient for analysis of intestinal fat deposition (IFD) by hydrophobic
lipid dye-staining and photometric quantification in the intact animal. Fluorescent probe Nile
red has been validated through lipid extraction, separation with thin layer chromatography,
and quantification with gas chromatography.4,5 Recently, Nile red staining in vitro has been
recommended in comparison with coherent anti-Stokes Raman scattering microscopy.6,7 C.
elegans also has rapid reproduction cycles and large brood sizes that allow for the
performance of a variety of cellular, molecular, genetic, and behavioral analyses.8 The
pharyngeal pumping rate (PPR) in C. elegans is correlated to the lifespan and is a wellaccepted surrogate marker for studies of aging.9 The biosynthetic and metabolic pathways of
C. elegans are highly conserved and are shared with mammalian systems. More than 65% of
the genes relating to human diseases are preserved in C. elegans,1,10–12 approximately, 3500
genetically manipulated strains are marvelous models for unraveling human diseases,13–16
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and the C. elegans model organisms are helpful to answer pharmacological questions of
human diseases.
Question I

Author Manuscript

Betahistine and olanzapine-induced IFD—Betahistine was approved in the United
States for the treatment of vertigo in 1968 when safety was the only criteria for approval by
the US Food and Drug Administration (NDA 14–241). It was taken off the market in the
United States only in 1972 because required efficacy studies were never done (http://
money.cnn.com/2007/08/09/magazines/business2/obesity_pill.biz2/index.htm). Betahistine
is currently used throughout the rest of the world and the manufacturer estimates that 60
million individuals have used the drug with minimal and tolerable side effects [Serc
(Betahistine Dihydrochloride), Product Monograph; Solvay Pharma, India, Ltd. Date of
revision: September 23, 2003, control #075422]. The adverse drug reaction information
system of British Medicine Control Agency lists 299 reports for a total of 461 adverse
reactions to betahistine. The most common adverse reactions are nausea (n = 19),
vomiting,17 diarrhea,18 headache,19 and pruritis.17 Not only does betahistine have a good
record of safety but a study in guinea pigs suggests it may also be effective for the treatment
of vertigo.20

Author Manuscript
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Betahistine, a histamine-1 receptor (H1R) agonist and a partial antagonist of the presynaptic
autoreceptors of the histamine-3 receptor (H3R), is an orally administered drug that affects
central nervous system function by acting on 2 G protein–coupled metabotropic receptors.
The H1R seems to control feeding and body weight in animals18 by reducing food intake
mediated through H1R21 and increasing feeding through H1R antagonism in rodents.22
Overwhelming weight gain characterizes the second-generation antipsychotics (SGA),
which antagonize H1R, as occurs with olanzapine, whereas betahistine has been effective in
combating olanzapine-induced weight gain.23 Betahistine may reverse the effect of H3R
antagonists by uncoupling the G protein–coupled reactions to release the H1R from
inhibition by the H3R.17 In patients, taking 12.5–17.7 mg of olanzapine per day, the average
weight gain was 12 kg at 1 year.23 Finding optimal doses of betahistine may reduce the
adverse effect of weight gain by SGA during successful treatment of psychiatric disorders.
Betahistine, however, is metabolized rapidly making it difficult to measure blood levels of
the active compound and determine the optimal ratio.24 In C. elegans, olanzapine has been
shown to increase IFD by 15% in 48 hours.25 The increased IFD may provide an opportunity
to define the optimal ratio of betahistine to olanzapine and to block the olanzapine-induced
weight gain. Using C. elegans also gets around the problem of rapid betahistine metabolism,
since betahistine is added to the solution from which C elegans constantly consumes in the
culture dish. Although C. elegans does not have a histamine receptor per se, it has
octopamine receptors,26 whereas octopamine is also a beta(3)-adrenergic agonist in
humans.27,28 Octopamine receptors have been demonstrated to selectively bind epinastine, a
H1R antagonist in humans, suggesting that the octopamine is a homolog of the human H1R
and cause moderate weight loss in rodents.29,30 In view of these findings and the response to
olanzapine with rapid fat gain, we felt that C. elegans was an appropriate model to explore
an optimal ratio of betahistine to olanzapine for blocking fat gain.
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Mechanism of action of antiobesity drug candidate AB-101—AB-101 is as
successful as metformin, verapamil, or sibutramine, in treating diabetes, hypertension, or
obesity, respectively, in rodents (unpublished data). These effects were associated with
increased fat oxidation, elevated metabolic rate, and reduced serum free fatty acids. The
mechanism of action of AB-101, however, is not known. Metabolism of long-chain fatty
acids requires several crucial pathways: (1) intracellular transport of the membrane fatty acid
transporter cluster differentiation transport protein (CD36), where CD36 is an upstream
regulator of CPT-1 in transporting fatty acids, (2) acetyl-CoA synthetase (ACS)
enzymatically binds fatty acids to acyl CoA to form acetyl-CoA, (3) the fatty acid must be
bound to carnitine through the enzymes carnitine palmitoyltranferases (CPT-1 and CPT-2) to
move across the 2 mitochondrial membranes and enter the tricarboxylic acid cycle or
electron transport chain for energy production, and (4) malonyl CoA that is synthesized by
acetyl coenzyme A carboxylase (ACC) and downregulates CPT-1 based on the need for lipid
synthesis.
CPT-1, ACC, and ACS are also essential elements in the fat oxidation pathway in C. elegans.
The key enzyme CPT-1 is not able to stimulate fat oxidation in the absence of ACS or CD36,
and CPT-1 cannot be downregulated in the absence of ACC. Protease inhibitors atazanavir
and ritonavir have been shown to inhibit CPT-1 and CD36 and to increase fat deposition in
wild-type C. elegans.31 We hypothesized that AB-101–induced body fat reduction required
mechanisms that involved upregulation of CPT-1, then AB-101 should reduce fat deposition
by removing the proteinase inhibitor–induced inhibitory effect on CPT-1 and CD36.
Likewise, the AB-101–induced body fat reduction would be absent in the ACS null mutant.

Author Manuscript

The present report describes 2 proof-of-concept studies using C. elegans to answer
pharmacological questions: (1) to determine an optimal ratio of betahistine to olanzapine
required to minimize olanzapine-induced IFD using wild-type C. elegans and (2) using
inhibitors of CPT-1 and the ACS null mutant to explore the mechanism of action of AB-101.

MATERIALS AND METHODS
All strains of C. elegans and a standard laboratory food source of E. coli (OP50) were
obtained from the Caenorhabditis Genetics Center (CGC, University of Minnesota, MN).
Animals were cultured in an agar dish in a low-temperature incubator at 20°C. A day before
the experiment, 200 μL of a feeding media was added to the agar dish, and the animals were
allowed to eat ad libitum. Control animals were fed with 200 μL of the E. coli only.

Author Manuscript

C. elegans culture
Age-synchronized C. elegans were grown on nematode growth media (NGM) agar plates
(35-mm diameter) in a 20°C incubator (Revco Tech., Nashville, NC). Nematode growth
media culture contained 3 g of NaCl, 20 g of Bacto-agar, 2.5 g of Bacto-peptone (Becton,
Sparks, MD), 0.005 mL of 0.1% cholesterol solution in 95% ethanol, and 975 mL of dH2O,
with further addition of 1 mL of 1 M CaCl2, 1 mL of 1 M MgSO4, and 25 mL of 1 M KPO4,
pH 6 after autoclaving. Cultures were fed ad libitum with Luria Bertani broth (200 μL)
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containing 5 × 108 to 5 × 1011 CFU/mL E. coli OP50.32 Mature, gravid C. elegans were
individually transferred onto agar plates and treated with a 1:1 solution of 0.4 M NaCl and 1
M NaOH to dissolve the C. elegans and release the viable eggs. All experimental treatments
were conducted 3 days after hatching. Age synchronization was achieved by transferring
worms every other day. Two hundred microliters of each treatment was added to fresh agar
plates before the transfer. Each group of worms was collected and fixed at 15–20 days as
previously described.33
Study 1—Wild-type C. elegans (N2) were divided into 3 groups: group 1 served as an
untreated control and received OP50 only; group 2 was divided into 2 subgroups treated with
(1) olanzapine (53 μg/mL) or (2) betahistine (763 μg/mL) based on the doses of atypical
antipsychotic medication in humans; and group 3 was treated with both olanzapine (53
μg/mL) and betahistine (763 μg/mL).

Author Manuscript

Study 2—C. elegans N2 or acs-4(ok2872) III/hT2[bli-4(e937) let-? (q782) qIs48](I;III)
(ACS mutant) were used. Group 1 was the control that received OP50 only. Group 2, 3, and
4 were further subdivided and received additional treatments. Group 2 was fed AB-101: (1)
0.3% and (2) 1%. Group 3 received the protease inhibitors atazanavir plus ritonavir at the
following combined doses: (1) 3.3 μmole/L/0.83 μmole/L, (2) 6.7 μmole/L/2.5 μmole/L, (3)
20 μmole/L/5 μmole/L, and (4) 33 μmole/L/8.3 μmole/L (Table 1). Group 4 received
AB-101 (1%) plus the 3 combinations of the protease inhibitors as in group 3a, b, and c.
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At the end of the experiments, an S-basal (see below) solution (1 mL/dish) was used to wash
the animals. The solution containing the animals was centrifuged for 20 seconds at 3000
rpm, and this procedure was repeated twice. Animals were then fixed with 4%
paraformaldehyde for over 2 hours at 4°C and washed twice with PBS for 5 minutes. The
lipid staining dye Nile red was selected to determine the IFD response to the treatments.
Nile red was dissolved in acetone. Glycerol–water (75:25) was added into the stock solution.
Fifty microliters of the working solution was applied to the animals for 10 minutes. A drop
of Fluoromount-G was applied to a glass slide followed by 20 μL of the medium containing
Nile red stained animals. The slides were viewed with a fluorescence microscope (Nikon
Eclipse, Ti) equipped with a TRITC filter. Digital images were taken with Retiga 4000R and
fluorescence micrographs were taken. All data were analyzed offline. The line profiles of the
optical densities of the Nile red staining were determined using ImagePro Plus. Unit optical
densities (arbitrary units, fluorescent intensity/area) of Nile red labeled IFD were determined
for each group at the conclusion of the studies and were compared with their paired control
groups.

Author Manuscript

Statistics were performed using SAS (Version 9.3, SAS Institute Inc., Cary, NC). Data were
compared using the Student t test for IFD or analysis of covariance (ANCOVA) for PPR.
Statistical significance was set at P ≤ 0.05.

RESULTS
The first study proved that betahistine inhibited the olanzapine-induced increased IFD in C.
elegans. The second study confirmed that AB-101 decreased fat deposition in N2, also
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reduced the increased fat deposition that was induced by protease inhibitors in N2, and had
no effect on the low IFD of the ACS mutant.
Study 1
The control group displayed normal IFD (Figure 1A). Animals receiving olanzapine (53
μg/mL) alone showed a 12.1 ± 0.1% increase of fat deposition in C. elegans (N2) (Figure
1B, P < 0.02). Betahistine (763 μg/mL) alone did not alter the fluorescence intensity of Neil
red (Figure 1C, P > 0.05) but did significantly block fat accumulation engendered by
olanzapine in the wild-type C. elegans. Combination of olanzapine (53 μg/mL) with
betahistine (763 μg/mL) reduced IFD compared with the olanzapine-treated group by 39.3
± 0.01% (P < 0.05) (Figure 1D, E).
Study 2

Author Manuscript

AB-101 (1.0%) significantly reduced the IFD (Figure 2A, P < 0.05) without impairing
growth in N2 animals (data not shown). Both doses elevated the PPR (P < 0.05) (Figure 3A).
The Nile red intensity was dramatically lower in acs-4 mutant (Figure 2B), whereas the
pumping rate was elevated in the presence of AB-101 (Figure 3B, P < 0.05). Combinations
of protease inhibitors atazanavir and ritonavir at the higher dosage (Table 1) showed a
tendency to elevate IFD by themselves (Figure 2C, P > 0.05), which was reversed in the
presence of AB-101 (1.0%) in the N2 animals (Figure 2D, P < 0.05). The PPR was reduced
with or without AB-101 in the presence of atazanavir and ritonavir in N2 (Figure 3C, D, P <
0.05).

DISCUSSION
Author Manuscript
Author Manuscript

The 2 studies proved the practical use of C. elegans model organism to address
pharmacological questions. These data are promising in terms of understanding the
mechanism of action(s) required by the FDA for potential new drug products. Betahistine
does not affect food intake and appetite in humans whereas reduces body weight in healthy
and middle-aged obese women,34,35 it did not reduce IFD in this study. The most important
observation is the blocking by betahistine of olanzapine-induced fat gain. The first study
confirmed that betahistine inhibited the olanzapine-induced IFD in C. elegans as has been
seen in rats and in humans.23,36 Olanzapine has been shown to increase fat in C. elegans.19
We demonstrated that the ratio of betahistine to olanzapine used in this study completely
inhibited the olanzapine-induced fat gain. This information suggests that the partial
inhibition of olanzapine-induced weight gain seen in the human and rat studies may
represent an inadequate ratio of the 2 drugs or a consequence of rapid betahistine
metabolism. Clearly, more dose–response work is needed going forward to determine the
optimal ratio of betahistine to olanzapine capable of maximizing the inhibitory effect on the
olanzapine-induced weight gain and a timed-release form of betahistine may also be
required. Successful titration of the ratio of the olanzapine/betahistine combination may be
extended to titration of betahistine and other SGAs with weight-gaining properties. The C.
elegans model certainly is cost effective for initial screening to determine the optimal dose–
ratio when compared with studies performed in rodents, which incur greater cost and
necessitate a longer time to determine the correct answer. An additional advantage to C.
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elegans is that they are not regulated by animal care and use committees, making their use
much more time efficient from a paperwork perspective. Betahistine is very rapidly
metabolized so that measuring serum levels is impractical. By using the C. elegans model to
explore the optimal dose ratio of the drug combination, a more focused study to confirm this
ratio can be done in rodents and later in human clinical trials. Whether a time-released dose
of betahistine will be eventually needed in humans for optimal efficacy due to the rapid
metabolism remains to be determined.
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In the second study, using the ACS null mutant strain, we investigated a mechanism of
action of a new antiobesity candidate drug AB-101 that reduces IFD in the C. elegans model
by upregulating CPT-1. Treating the ACS mutant with AB-101 was ineffective suggesting
that the target of the drug was indeed in the CPT-1 fat oxidation pathway, which includes
ACS. Proteinase inhibitors that decrease fat oxidation by inhibiting CPT-1 and CD-36 did
increase fat accumulation in C. elegans. In addition, in the presence of proteinase inhibitors,
the fat accumulation was reversed by AB-101 treatment in C. elegans. These data confirmed
that AB-101 was working to decrease IFD by acting on the fat oxidation mediated by an
upregulation of CPT-1 because it reversed the reduction of CPT-1 activity induced by the
protease inhibitors. This study calls for additional work to determine whether the
upregulation of CPT-1 is by direct stimulation of the enzyme or, more likely, by inhibition of
ACC, which controls the synthesis of malonyl CoA, an inhibitor of CPT-1.

Author Manuscript

CONCLUSIONS
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C. elegans model is evolutionarily distant from higher species. Despite its convenience and
cost effectiveness, confirmatory studies will still be needed in higher animal model
vertebrates. The fact that about 1/3 genes involved in human diseases are not represented in
C. elegans presents limitations to the study of some human diseases and caution should be
exercised in studying those human diseases. We suggest that using C. elegans model should
be considered for initial proof-of-concept studies that are viewed as screening studies, which
will require verification in vertebrate models before human studies.
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FIGURE 1.

Author Manuscript

Fluorescent intensity of Nile red representing IFD. (A) Control, (B) olanzapine (53 μg)
increased the fluorescent intensity, (C) betahistine (763 μg) did not increase the intensity,
and (D) the olanzapine-elevated fluorescent intensity was reduced in the presence of
betahistine. (E) Quantification of the Nile red fluorescence intensity of the IFD. Statistical
significance (P < 0.05) is illustrated between columns labeled with 1 or between groups
labeled with 2. *P < 0.05.
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FIGURE 2.
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AB-101 (1.0%) reduced IFD in N2 but not the acs mutant. (A) AB-101 reduced the
fluorescence intensity in N2 (●, P < 0.05). Low fluorescent intensity of Neil red was
detected in acs-4(ok2872) III/hT2[bli-4(e937) let-?(q782) qIs48](I;III) with or without
AB-101 (○). (B) Combination of atazanavir and ritonavir had a tendency to increase the
fluorescent intensity (○). The elevation of the fluorescent intensity in the presence of the
combination of atazanavir and ritonavir was reduced by AB-101 (●, P < 0.05). *P < 0.05
compared with control.
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FIGURE 3.
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AB-101 (1.0%) elevated the PPR in N2 and ACS mutant but not in the presence of protease
inhibitors. (A) AB-101 increased the pumping rate in N2 (P < 0.05). (B) AB-101 increased
the pumping rate in acs-4(ok2872) III/hT2[bli-4 (e937) let-?(q782) qIs48](I;III). (C)
Combination of atazanavir and ritonavir reduced the pumping rate in N2 (P < 0.05). (D)
AB-101 did not reverse the reduced pumping rate by combination of atazanavir and
ritonavir.
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